Abstract

Since the end of 2019, the whole world has been suffering through the pandemic of the new Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2). Pain is a most common symptom during Novel Coronavirus Disease 2019 (COVID-19). According to the World Health Organization, patients suffering from COVID-19 show symptoms of muscle pain (myalgia) and/or joint pain (arthralgia), sore throat and headache. We present a narrative review of musculoskeletal manifestation and available treatment options. Our aim is to update the pain physicians and physicians working with COVID-19 Patients about possible pathogenesis of myalgia and best proposed treatment available.

Research data for this article is based on literature search which has been referenced in the text. There was no preliminary data. A search of PubMed and Google Scholar was done. We found 15 scientific papers on the related topics. Based on the review we infer that in addition to the cytokine storm experienced by many COVID-19 patients, certain additional factors such as severity of COVID-19 infection contributes to post covid myalgia and fatigue.

Keywords: Coronavirus; Neuropathy; Myalgia; Arthralgia; Headache; Opioids

References

1. Lippi G., et al. “Myalgia may not be associated with severity of coronavirus disease 2019 (COVID-19)”. World Journal of Emergency Medicine 11 (2020): 193-194.
2. Cure E and Cumhur Cure M. “Comment on “Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19”. Journal of Medical Virology (2020).
3. Cure E and Cumhur Cure M. “Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic”. Diabetes and Metabolic Syndrome 14 (2020): 349-350.
4. Cure E and Cumhur Cure M. “Comment on ‘Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade”. Nephron 144 (2020): 251-252.
5. Echeverría-Rodríguez O., et al. “Angiotensin- (1-7) participates in enhanced skeletal muscle insulin sensitivity after a bout of exercise”. Journal of the Endocrine Society 4 (2020).
6. Cure E and Cumhur Cure M. “Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis”. Diabetes and Metabolic Syndrome 14 (2020): 405-406.
7. Juel C and Halestrap AP. “Lactate transport in skeletal muscle - role and regulation of the monocarboxylate transporter”. Journal of Physiology 517 (1999): 633-642.
8. Messonnier L., et al. “Importance of pH regulation and lactate/H+ transport capacity for work production during supramaximal exercise in humans”. Journal of Applied Physiology 102 (2007): 1936-1944.
9. Liang CZ., et al. “The relationship between low pH in intervertebral discs and low back pain: a systematic review”. Archives of Medical Science 8 (2012): 952-956.
10. Queme LF., et al. “Peripheral mechanisms of ischemic myalgia”. Frontiers in Cellular Neuroscience 11 (2017): 419.
11. https://scroll.in/article/967801/why do some coronavirus patients suffer chronic fatigue even after recovery
12. Madhok J and Mihm FG. “Rethinking sedation during prolonged mechanical ventilation for COVID-19 respiratory failure”. Anesthesia and Analgesia 131 (2020): e123-e124.
13. Hanidziar D and Bittner E. “Sedation of mechanically ventilated COVID-19 patients: Challenges and special considerations”. Anesthesia and Analgesia 131 (2020): e40-e41.
14. Russell B., et al. “COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting?” Ecancermedicalscience 14 (2020): 1023.
15. World Health Organization. The Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Patients with COVID-19 (2020).
16. Shanthanna H., et al. “Caring for patients with pain during the COVID-19 pandemic: Consensus recommendations from an international expert panel”. Anaesthesia 75 (2020): 935-944.
17. Vozoris NT. “Opioid utility for dyspnea in chronic obstructive pulmonary disease: A Complicated and controversial story”. Annals of Palliative Medicine 9 (2020): 571-578.
18. Vozoris NT., et al. “Predictors of opioid-related adverse pulmonary events among older adults with COPD”. Annals of the American Thoracic Society (2020).
19. Vozoris NT., et al. “Incident opioid drug use and adverse respiratory outcomes among older adults with COPD”. European Respiratory Journal 48 (2016): 683-693.
20. Flores LR., et al. “Mechanisms of morphine-induced immunosuppression: Effect of acute morphine administration on lymphocyte trafficking”. Journal of Pharmacology and Experimental Therapeutics 272 (1995): 1246-1251.
21. Hernandez MC., et al. “Immunosuppression by Morphine is mediated by central pathways”. Journal of Pharmacology and Experimental Therapeutics 267 (1993): 1336-1341.
22. Davis MP. “Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain”. Journal of Supportive Oncology 10 (2012): 209-219.
23. Davis MP., et al. “Treating chronic pain: An Overview of clinical studies centered on the buprenorphine option”. Drugs 78 (2018): 1211-1228.
24. Arabi YM., et al. “Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome”. American Journal of Respiratory and Critical Care Medicine 197 (2018): 757-767.
25. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (NCoV) Infection Is Suspected; World Health Organization: Geneva, Switzerland (2020).
26. Mao L., et al. “Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China”. JAMA Neurology 77 (2020): 1-9.
27. Abdelnour L., et al. “COVID 19 infection presenting as motor peripheral neuropathy”. Journal of the Formosan Medical Association 119 (2020): 1119-1120.
28. Montalvan V., et al. “Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review”. Clinical Neurology and Neurosurgery 194 (2020): 105921.
29. Pleasure SJ., et al. “The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: Neurologists move to the frontlines”. JAMA Neurology 77 (2020): 679-680.
30. Li YC., et al. “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients”. Journal of Medical Virology 92 (2020): 552-555.
31. Devlin JW., et al. “Strategies to optimize ICU liberation (A to F) bundle performance in critically Ill adults with coronavirus disease 2019”. Critical Care Explorations 2 (2020): e0139.
32. Finnerup NB., et al. “Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis”. Lancet Neurology 14 (2015): 162-173.
33. Brooks KG and Kessler TL. “Treatments for neuropathic pain”. Clinical pharmacology 9 (2017): 1-14.
34. Pop-Busui R., et al. “Diabetic neuropathy: A position statement by the american diabetes association”. Diabetes Care 40 (2017): 136-154.

Citation

Citation: Manjiri Ranade., et al. “Systematic Review of Post Covid Myalgia Literature".Acta Scientific Orthopaedics 4.2 (2021): 73-77.

Copyright

Copyright: © 2021 Manjiri Ranade., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.